|
|
Volumn 384, Issue 9944, 2014, Pages 649-
|
|
Experimental Ebola drugs enter the limelight
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
DIHYDROLIPOAMIDE DEHYDROGENASE;
EBOLA VACCINE;
EPITOPE;
GLYCOPROTEIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
INTERFERON;
MONOCLONAL ANTIBODY;
SMALL INTERFERING RNA;
RNA POLYMERASE;
VIRUS GLYCOPROTEIN;
EBOLA HEMORRHAGIC FEVER;
EBOLA VIRUS;
EPIDEMIC;
HEALTH CARE PERSONNEL;
HEALTH CARE QUALITY;
HUMAN;
INTENSIVE CARE;
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
UNITED STATES;
WEST AFRICAN;
WORLD HEALTH ORGANIZATION;
CONTROL STRATEGY;
INFECTION CONTROL;
PHASE 1 CLINICAL TRIAL (TOPIC);
PROTECTIVE EQUIPMENT;
PROTEIN EXPRESSION;
AFRICA;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIVIRAL AGENTS;
DRUGS, INVESTIGATIONAL;
HEMORRHAGIC FEVER, EBOLA;
HUMANS;
RNA, SMALL INTERFERING;
VIRAL VACCINES;
WORLD HEALTH ORGANIZATION;
|
|
EID: 84906679888
PISSN: 01406736
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/S0140-6736(14)61371-4 Document Type: Note |
|
Times cited : (19)
|
|
References (0)
|
